# Posaconazole

Source: https://onco.cc/drugs/posaconazole/  
OnCo record `posaconazole` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Posaconazole is an antifungal medicine. Its label includes preventing mould and yeast infections in people with blood cancers whose white cells stay low for a long time after chemotherapy.

## Summary

The Noxafil label covers treatment of invasive aspergillosis, and "prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy", as well as oropharyngeal candidiasis. The ECIL-10 guideline (2025) considers isavuconazole for adults in remission induction for acute myeloid leukaemia "for whom posaconazole is not appropriate", and notes literature support for posaconazole during the first four cycles of azacitidine in high-risk MDS. ECIL notes that the drug interaction between triazoles and vincristine, part of most acute lymphoblastic leukaemia regimens, hampers antifungal prophylaxis there. The NDA was first approved on 15 September 2006.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-11-11
- Tags: supportive; generic; supportive-care-gaps-2026-11
- Brand: Noxafil
- Modality: Azole antifungal (oral, intravenous)
- Mechanism: A triazole antifungal that blocks ergosterol synthesis in the fungal cell membrane.
- Approvals: US 2006: Prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients (HSCT with GVHD, haematological malignancies with prolonged neutropenia from chemotherapy); invasive aspergillosis; oropharyngeal candidiasis

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Posaconazole
- US label (DailyMed): Noxafil: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84
- Primary antifungal prophylaxis in hematological malignancies: updated ECIL-10 clinical practice guidelines (Leukemia 2025): https://doi.org/10.1038/s41375-025-02586-7

## Connected records

- drugs: [Valaciclovir](https://onco.cc/drugs/valaciclovir/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/)
- terms: [Graft-versus-host disease (GVHD) and graft-versus-leukaemia](https://onco.cc/terms/gvhd/), [Neutropenia](https://onco.cc/terms/neutropenia/)

---
JSON: https://onco.cc/api/v1/entities/posaconazole.json